Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension
ConclusionThe travoprost intraocular implant demonstrated robust IOP-lowering and substantially reduced topical IOP-lowering medication burden for up to 36 months following a single administration, while maintaining a favorable safety profile. The travoprost intraocular implant promises to be a meaningful addition to the interventional glaucoma armamentarium by addressing the key shortcomings of topical IOP-lowering medications, including low adherence and topical side effects while controlling IOP for up to 36 months.Trial RegistryClinicalTrials.gov identifier NCT02754596 registered 28 April 2016. (Source: Drugs)
Source: Drugs - December 7, 2023 Category: Drugs & Pharmacology Source Type: research
Primary Open-Angle Glaucoma Progression in Glaucoma Patients with Unchanged Topical Treatment over 3 Years - Retrospective Observational Cohort Analysis
CONCLUSION: Both groups had comparable baseline, as well as mean overall IOP. However, the course of IOP levels over time was different in the two groups, showing earlier and more pronounced long-term drift in the prostaglandin analog-treated group. RNFL thickness was comparable at baseline, however, RNFL thinning over time was more pronounced in the prostaglandin analog-treated group. There were no statistical differences between the groups in terms of VF MD at baseline and over time.PMID:37164404 | DOI:10.1055/a-2004-4943 (Source: Klinische Monatsblatter fur Augenheilkunde)
Source: Klinische Monatsblatter fur Augenheilkunde - May 10, 2023 Category: Opthalmology Authors: Yasemin Saruhan Pascal W Hasler Konstantin Gugleta Source Type: research
Effects of topical prostaglandin therapy on corneal layers thickness in primary open-angle glaucoma patients using anterior segment optical coherence tomography
ConclusionTopical treatment with latanoprost, bimatoprost, and travoprost affects each layer of the cornea separately according to the active and protective substances contained in these eye drops. On the other hand, the thinning effect on the corneal layers was similar in these three drugs because there was no significant difference between the three groups in the total amount of thinning of the corneal layers during the follow-up period. (Source: International Ophthalmology)
Source: International Ophthalmology - April 17, 2023 Category: Opthalmology Source Type: research
FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma
Exp Eye Res. 2023 Feb 18:109415. doi: 10.1016/j.exer.2023.109415. Online ahead of print.ABSTRACTProstaglandin (PG) receptors represent important druggable targets due to the many diverse actions of PGs in the body. From an ocular perspective, the discovery, development, and health agency approvals of prostaglandin F (FP) receptor agonists (FPAs) have revolutionized the medical treatment of ocular hypertension (OHT) and glaucoma. FPAs, such as latanoprost, travoprost, bimatoprost, and tafluprost, powerfully lower and control intraocular pressure (IOP), and became first-line therapeutics to treat this leading cause of blindn...
Source: Experimental Eye Research - February 21, 2023 Category: Opthalmology Authors: Najam A Sharif Noriko Odani-Kawabata Fenghe Lu Leonard Pinchuk Source Type: research
Trends in development and quality assessment of pharmaceutical formulations - F2 α analogues in the glaucoma treatment
Eur J Pharm Sci. 2022 Oct 28;180:106315. doi: 10.1016/j.ejps.2022.106315. Online ahead of print.ABSTRACTThe ocular delivery route presents a number of challenges in terms of drug administration and bioavailability. The low bioavailability following topical ophthalmic administration shows that there is a clear need for in-depth research aimed at finding both more efficacious molecules and formulations precisely targeted at the site of action. Continuous technological development will eventually result in improved bioavailability, lower dosages, reduced toxicity, fewer adverse effects, and thus better patient compliance and ...
Source: European Journal of Pharmaceutical Sciences - November 11, 2022 Category: Drugs & Pharmacology Authors: Katarzyna Asendrych-Wicik Jakub Zarczuk Katarzyna Walaszek Tomasz Ciach Magdalena Markowicz-Piasecka Source Type: research
Trends in development and quality assessment of pharmaceutical formulations - F2 α analogues in the glaucoma treatment
Eur J Pharm Sci. 2022 Oct 28;180:106315. doi: 10.1016/j.ejps.2022.106315. Online ahead of print.ABSTRACTThe ocular delivery route presents a number of challenges in terms of drug administration and bioavailability. The low bioavailability following topical ophthalmic administration shows that there is a clear need for in-depth research aimed at finding both more efficacious molecules and formulations precisely targeted at the site of action. Continuous technological development will eventually result in improved bioavailability, lower dosages, reduced toxicity, fewer adverse effects, and thus better patient compliance and ...
Source: European Journal of Pharmaceutical Sciences - November 11, 2022 Category: Drugs & Pharmacology Authors: Katarzyna Asendrych-Wicik Jakub Zarczuk Katarzyna Walaszek Tomasz Ciach Magdalena Markowicz-Piasecka Source Type: research
Trends in development and quality assessment of pharmaceutical formulations - F2 α analogues in the glaucoma treatment
Eur J Pharm Sci. 2022 Oct 28;180:106315. doi: 10.1016/j.ejps.2022.106315. Online ahead of print.ABSTRACTThe ocular delivery route presents a number of challenges in terms of drug administration and bioavailability. The low bioavailability following topical ophthalmic administration shows that there is a clear need for in-depth research aimed at finding both more efficacious molecules and formulations precisely targeted at the site of action. Continuous technological development will eventually result in improved bioavailability, lower dosages, reduced toxicity, fewer adverse effects, and thus better patient compliance and ...
Source: European Journal of Pharmaceutical Sciences - November 11, 2022 Category: Drugs & Pharmacology Authors: Katarzyna Asendrych-Wicik Jakub Zarczuk Katarzyna Walaszek Tomasz Ciach Magdalena Markowicz-Piasecka Source Type: research
Trends in development and quality assessment of pharmaceutical formulations - F2 α analogues in the glaucoma treatment
Eur J Pharm Sci. 2022 Oct 28;180:106315. doi: 10.1016/j.ejps.2022.106315. Online ahead of print.ABSTRACTThe ocular delivery route presents a number of challenges in terms of drug administration and bioavailability. The low bioavailability following topical ophthalmic administration shows that there is a clear need for in-depth research aimed at finding both more efficacious molecules and formulations precisely targeted at the site of action. Continuous technological development will eventually result in improved bioavailability, lower dosages, reduced toxicity, fewer adverse effects, and thus better patient compliance and ...
Source: European Journal of Pharmaceutical Sciences - November 11, 2022 Category: Drugs & Pharmacology Authors: Katarzyna Asendrych-Wicik Jakub Zarczuk Katarzyna Walaszek Tomasz Ciach Magdalena Markowicz-Piasecka Source Type: research
